Baseline clinical features predict visual outcome in young patients with central retinal vein occlusion

Koh, Yeo-Yang; Lai, Chi-Chun; Wu, Wei‐Chi; Hwang, Yih-Shiou; Chen, Kuan‐Jen; Wang, Nan-Kai; Chen, Tun-Lu; Huang, Jerry Chien-Chieh; Yeung, Ling

doi:10.1007/s00417-020-04679-8

Cited by 8 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Young patients with CRVO are more likely to develop optic disc swelling [50]. Papilloedema was also reported to be a good predictor of visual prognosis in CRVO [1,59]. The location of obstruction, inflammatory factors, and VEGF levels may play a role in the pathophysiology of swelling of the optic nerve head in young patients.…”

Section: Differences In Clinical Manifestationsmentioning

confidence: 97%

“…Larsen et al showed that CRVO patients with macular edema had a mean age of 65.5 years and received a mean of 8.1 ± 2.8 injections of anti-VEGF therapy injections (ranibizumab 0.5 mg) in the first 12 months of treatment [62]. Meanwhile, Koh et al reported that young patients with CRVO had a mean age of 37.6 ± 8.5 years; 34% of eyes did not require anti-VEGF therapy injections, and 75% of the remaining eyes only required B 3 injections [1]. Rothman's study showed that the number of anti-VEGF injections was lower in young patients than in elderly patients during the same time period (3.0 ± 4.5 vs. 7.7 ± 5.5) [2].…”

Section: Differences In Treatmentmentioning

confidence: 99%

“…Retinal laser coagulation can be performed in cases where there are extensive non-perfused areas on the retina and retinal or iris neovascularization. Rothman et al reported that young patients required fewer sessions of panretinal photocoagulation than elderly patients [1]. However, Ye et al showed that there was no difference in the number of laser photocoagulation sessions between young and elderly patients with RVO [66], and Eah et al also believed that the frequency of laser photocoagulation is not significantly affected by age [18].…”

Section: Differences In Treatmentmentioning

confidence: 99%

“…According to previous studies, the incidence of CRVO in patients \ 50 years old is 0.23/1000, whereas that in patients C 50 years old is 1.95/1000 [9]. CRVO in young patients accounts for 10-15% of the total number of CRVO cases [10], and most studies have shown that CRVO in young patients is more prevalent in men than in women [1,5,11,12]. Young people are more sensitive to vision loss, and due to the rarity of the condition in these patients, CRVO in young patients is often reported, resulting in the overestimation of the number of cases.…”

Section: Introductionmentioning

confidence: 99%

“…CRVO causes varying degrees of visual impairment. Currently, the literature defines CRVO cases in patients \ 50 years old as CRVO in the young [1][2][3][4][5][6]. However, some studies have defined CRVO in the young as that occurring in patients either \ 40 [7] or \ 55 [8] years old.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinical Features of Central Retinal Vein Occlusion in Young Patients

et al. 2022

View full text Add to dashboard Cite

Retinal vein occlusion (RVO) is the second most common retinal vascular disease. Central RVO (CRVO), in which obstruction occurs posterior to the lamina cribrosa due to various causes, manifests with extensive venous tortuosity, dilatation of blood vessels in the four quadrants, and retinal hemorrhage. The presence of macular edema decreases visual acuity in patients with CRVO, especially in elderly patients with hypertension, hyperlipidemia, and diabetes. In the last decade, treatment modalities for CRVO have improved, with antivascular endothelial growth factor agents being widely used as treatment. However, there are cases of refractory or recurrent macular edema. Moreover, CRVO also occurs in young patients. This article reviews previous studies and case reports and summarizes the differences in etiological factors, clinical manifestations, treatment, and prognosis between young and elderly patients. Due to the low incidence of CRVO in young patients, clinical data from these age groups are limited. Hence, further studies are warranted to explore the differences between age groups to improve individualization of treatment of young patients.

show abstract

Section: Differences In Clinical Manifestationsmentioning

confidence: 97%

Section: Differences In Treatmentmentioning

confidence: 99%

Section: Differences In Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical Features of Central Retinal Vein Occlusion in Young Patients

et al. 2022

View full text Add to dashboard Cite

show abstract

Postponed care due to COVID-19 lockdown impact on visual acuity of retinal vein occlusion patients: a large cohort

Cohen

Shor

Segal

et al. 2022

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

Purpose To evaluate the impact of postponed care attributed to coronavirus disease (COVID-19) pandemic lockdowns on visual acuity and the number of anti-VEGF injections in patients with retinal vein occlusion (RVO). Methods A multicenter, retrospective study of consecutive RVO patients previously treated with anti-VEGF injections, which compared data from pre- (2019) and during (2020) COVID-19 lockdown period. Results A total of 814 RVO patients with a mean age of 72.8 years met the inclusion criteria. Of them, 439 patients were assessed in 2019 and 375 in 2020. There was no significant difference between the COVID-19 and pre-COVID-19 period in terms of baseline and final BCVA ( p = 0.7 and 0.9 respectively), but there was a significantly reduced mean number of anti-VEGF injections during the COVID-19 period (5.0 and. 5.9 respectively, p < 0.01), with a constant lower ratio of injections per patient. A noticeable decline was found during March–May ( p < 0.01) in 2020. Baseline BCVA (0.69, p < 0.01) and the number of injections (− 0.01, p = 0.01) were predictors of final BCVA. Conclusions In a large cohort of RVO patients, during 2020 lockdowns imposed due to the COVID-19 pandemic, a significant reduction in the annual number of anti-VEGF injections was noted. The postponed care did not result in a significant impact on the final BCVA. Baseline BCVA and the number of annual injections serve as predictors for final BCVA in RVO patients.

show abstract